Tamoxifen is a cytostatic oestrogen receptor antagonist used extensively for the treatment of hormonally sensitive breast cancer. Soltamox is the only oral liquid presentation of tamoxifen licensed in the UK and Rosemont holds a worldwide patent covering this product.
ORCA Pharm will be responsible for the marketing and distribution of the product within Germany. Rosemont will manufacture Soltamox at its facility in Leeds, UK and will earn manufacturing profits on each unit produced. Additionally, Rosemont will receive profit share payments based on sales of Soltamox into the German wholesalers.
In addition to the 150ml bottles of Soltamox sold within the UK, a new 250ml size bottle will be marketed in Germany in line with local prescribing trends.
“We are exceptionally pleased to enter into this agreement with ORCA Pharm GmbH in Germany,” said Christopher Clement, Savient’s CEO & president. “They are well positioned to market this important niche product in the German oncology sector.”